Nextbiomedical

At a glance

Nextbiomedical filed 23 disclosures in the last 12 months, including 5 insider. The most recent key filing was on Jun 25.

Revenue for 2025 was ₩16.5B, up 72.7% on 2024. It made an operating loss of ₩719.5M. Debt was 23% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩9.1B and operating loss of ₩2.2B.

The 2025 annual report lists 81 employees with an average tenure of 3 years and average pay of ₩45.6M, #1627 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩158M each on average. It paid no cash dividend for 2025. 이돈행 and related parties held 30.29% at year end.

From the 2025 annual report

Staff: 81 (29 men, 52 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3.6B. Directors and auditors: 5, paid ₩789M in total.

No cash dividend was paid for 2025.

Largest shareholder

이돈행 holds 26.09%; with 7 related parties the group holds 30.29% of common shares at year end (from 32.21% at the start of the year).

Auditor: 대주회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary